Journal of Cancer Therapy

Volume 3, Issue 4 (August 2012)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.30  Citations  h5-index & Ranking

Pharmacological Isolation of Experimental Models of Drug-resistant Hepatocellular Carcinoma Cell Line

HTML  XML Download Download as PDF (Size: 124KB)  PP. 216-221  
DOI: 10.4236/jct.2012.34031    4,613 Downloads   8,887 Views  Citations

ABSTRACT

Drug resistance is one of the major challenges facing the success of chemotherapy against human hepatocarcinoma (HCC) as well as other types of cancer. Studies with cell lines can serve as initial screening for agents that could modulate drug resistance. Development of a good experimental model of drug-resistant cells is a prerequisite for the success of such cellular studies; but could be laborious and generally time-consuming. Additionally, the high mortality rate associated with advanced HCC calls for a probe into the mechanism of resistance by developing experimental model that mimics clinical method of its treatment. Consequently, we have reported a simplified method of selection of drug-resistant hepatocarcinoma cells from human hepatocellular carcinoma (HEPG2) cell line using pharmacologic agents, cisplatin (CDDP) and 5-fluorouracil (5-FU). HEPG2 cell line was incubated for 24 hours with different concentrations of CDDP (0 - 20 μM) or 5-FU (0 - 100 μM). Cell viability was assayed by CCK-8 (Cell Counting Kit) analysis, and the inhibitory concentrations (IC50) for CDDP and 5-FU were established by dose-dependent cytotoxicity curves. The IC50(s) were confirmed by flow cytometric analysis of cell death due to CDDP or 5-FU. Clinical method of treatment was imitated by treating the parental HEPG2 cell line in pulse, at the optimal concentration of either CDDP or 5-FU for 4 to 6 hours. Induction was repeated 6 times, whilst allowing the cells to attain at least 70% confluence between intervals of induction. The resultant drug-resistant sublines, (HEPG2CR) and (HEPG2FR) were found to be stable after over 3 months of drug withdrawal and maintenance in drug-free medium. This was done with the views of establishing a simple, efficient and direct protocol for the development of good cellular models for the study of drug resistance in liver cancer, with possible application in other cancer types.

Share and Cite:

B. Odii and P. Coussons, "Pharmacological Isolation of Experimental Models of Drug-resistant Hepatocellular Carcinoma Cell Line," Journal of Cancer Therapy, Vol. 3 No. 4, 2012, pp. 216-221. doi: 10.4236/jct.2012.34031.

Cited by

[1] Probing the Mechanism of Action of Cry41Aa on HepG2 through the Establishment of a Resistant Subline
Toxins, 2022
[2] Cytocidal activity of Cry41Aa, an anticancer toxin from Bacillus thuringiensis
2018
[3] Efecto del péptido sintético CIGB-300 en vías de señalización dependientes de CK2: implicancia en el tratamiento del cáncer de pulmón de células no pequeñas en …
2017
[4] Decellularized Matrix Produced by Mesenchymal Stem Cells Modulates Growth and Metabolic Activity of Hepatic Cell Cluster
ACS Biomaterials Science & Engineering, 2017
[5] Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy
European Journal of Pharmacology, 2017
[6] Efecto del péptido sintético CIGB-300 en vías de señalización dependientes de CK2: implicancia en el tratamiento del cáncer de pulmón de células no …
2017
[7] FTIR microspectroscopy defines early drug resistant human hepatocellular carcinoma (HepG2) cells
Experimental cell research, 2016
[8] Indirubin の生物学的親和性を利用した新規ハイブリッド型抗腫瘍剤の創製
2016
[9] Indirubin 3′-(O-oxiran-2-ylmethyl) oxime: A novel anticancer agent
Bioorganic & medicinal chemistry letters, 2015
[10] Roles of Transglutaminase 2 in development of drug resistance and metastasis by cancer cells.
2014
[11] Roles of Transglutaminase 2 in development of drug resistance and metastasis by cancer cells
2014

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.